AptarGroup, Inc. (FRA:AGT)

Germany flag Germany · Delayed Price · Currency is EUR
118.20
+2.30 (1.98%)
At close: Jul 20, 2026
Market Cap7.40B -15.6%
Revenue (ttm)3.36B +8.9%
Net Income335.35M +4.4%
EPS5.08 +7.0%
Shares Out n/a
PE Ratio22.05
Forward PE22.83
Dividend1.61 (1.39%)
Ex-Dividend DateMay 6, 2026
Volumen/a
Open114.80
Previous Close115.90
Day's Range114.80 - 118.20
52-Week Range93.75 - 138.50
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateJul 30, 2026

About AptarGroup

AptarGroup, Inc. designs and manufactures drug delivery, consumer product dispensing, and active material science solutions and services for the pharmaceutical, fragrance, facial skincare, color cosmetics, personal care, home care, and food and beverage markets. The company operates through three segments: Pharma, Beauty, and Closures. It provides dispensing pumps used to dispense sprays, liquids, or lotions from non-pressurized containers; fine-mist pumps for pharmaceutical and fragrance applications; and lotion pumps for viscous formulations,... [Read more]

Industry Plastics Products, not elsewhere classified
Founded 1992
Employees 14,000
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol AGT

Financial Performance

In 2025, AptarGroup's revenue was $3.78 billion, an increase of 5.42% compared to the previous year's $3.58 billion. Earnings were $392.79 million, an increase of 4.87%.

Financial numbers in USD Financial Statements

News

Aptar Declares Quarterly Dividend

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that the Board...

3 days ago - Business Wire

AptarGroup price target raised to $160 from $150 at Raymond James

Raymond James raised the firm’s price target on AptarGroup (ATR) to $160 from $150 and keeps an Outperform rating on the shares. Near-term Narcan destocking remains a headwind, but improving…

5 days ago - TheFly

BofA shakes up packaging and paper ratings with upgrade, four downgrades

As previously reported, BofA analyst George Staphos upgraded AptarGroup (ATR) to Buy from Neutral with a price target of $173, up from $148, as part of a Q2 preview for…

6 days ago - TheFly

AptarGroup upgraded to Buy from Neutral at BofA

BofA upgraded AptarGroup (ATR) to Buy from Neutral with a price target of $173, up from $148.

6 days ago - TheFly

Aptar Releases 2025 Corporate Sustainability Report

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Releases 2025 Corporate Sustainability Report.

4 weeks ago - Business Wire

AptarGroup Transcript: 16th Annual Wells Fargo Industrials & Materials Conference

Global operations delivered $3.8B in 2025 revenue, led by pharma, with strong innovation and a robust patent portfolio. Pharma remains the growth engine, supported by a diversified pipeline and new drug delivery technologies. Beauty and closures segments are recovering, with margin improvements expected as operational challenges are resolved.

5 weeks ago - Transcripts

AptarGroup Slides: 16th Annual Wells Fargo Industrials & Materials Conference

AptarGroup has posted slides in relation to its latest quarterly earnings report, which was published on June 9, 2026.

5 weeks ago - Filings

AptarGroup Transcript: Jefferies Global Healthcare Conference 2026

Global operations generated $3.8 billion in 2025, with Pharma as the main growth engine and a diverse, innovation-driven pipeline supporting a 7%-11% long-term growth target. Recent investments focus on automation, while injectables and high-value products show strong momentum.

6 weeks ago - Transcripts

AptarGroup Slides: FY 2026

AptarGroup has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 3, 2026.

6 weeks ago - Filings

Aptar Named a CDP Supplier Engagement Leader for the Sixth Consecutive Year

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Named a CDP Supplier Engagement Leader for the Sixth Consecutive Year.

6 weeks ago - Business Wire

Aptar to Participate in Upcoming Investor Conferences

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar to Participate in Upcoming Investor Conferences.

7 weeks ago - Business Wire

AptarGroup Transcript: AGM 2026

The meeting confirmed leadership succession, approved all voting items, and highlighted strong 2025 financial results, including increased sales and dividends. Strategic focus remains on Pharma growth, sustainability, and operational efficiency.

2 months ago - Transcripts

Advanced Technology Recycling (ATR) Announces That They Are Now Offering Wholesale Electronics to the General Public Through Their Online Auction Site

ITAD Firm, Advanced Technology Recycling (ATR), now offers wholesale electronics and computers to the general public through our online auction platform.

2 months ago - GlobeNewsWire

AptarGroup price target raised to $145 from $144 at Wells Fargo

Wells Fargo analyst Gabe Hajde raised the firm’s price target on AptarGroup (ATR) to $145 from $144 and keeps an Overweight rating on the shares. While the firm acknowledges the…

2 months ago - TheFly

AptarGroup Earnings Call Transcript: Q1 2026

Sales rose 11% year-over-year, but core sales were flat as emergency medicine destocking weighed on pharma. Beauty and closures saw margin pressure from mix and operational issues, but sequential improvements are expected. Free cash flow doubled and $131 million was returned to shareholders.

2 months ago - Transcripts

AptarGroup Earnings release: Q1 2026

AptarGroup released its Q1 2026 earnings on May 1, 2026, summarizing the period's financial results.

2 months ago - Filings

AptarGroup Slides: Q1 2026

AptarGroup has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 1, 2026.

2 months ago - Filings

AptarGroup Quarterly report: Q1 2026

AptarGroup has published its Q1 2026 quarterly earnings report on May 1, 2026.

2 months ago - Filings

AptarGroup reports Q1 EPS $1.19, consensus $1.15

Reports Q1 revenue $982.9M, consensus $955.9M. “Across the broader Pharma portfolio, we continue to see growing demand in key areas including GLP-1 therapies, biologics, systemic nasal drug delivery, ...

2 months ago - TheFly

AptarGroup sees Q2 EPS $1.32-$1.40, consensus $1.34

Regarding Aptar’s outlook, CEO Tanda stated, “Looking ahead to Q2, excluding destocking in emergency medicine within Pharma, we anticipate a solid quarter with growth across each segment. Outside of t...

2 months ago - TheFly

Aptar Reports First Quarter 2026 Results

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Reports First Quarter 2026 Results.

2 months ago - Business Wire

Aptar Digital Health Partners with Enable Injections for enFuse® Companion Digital Solution

CINCINNATI, April 08, 2026 (GLOBE NEWSWIRE) -- Aptar Digital Health, a global leader in digital health solutions enhancing the patient experience, and Enable Injections, Inc. (“Enable”), a healthcare ...

3 months ago - GlobeNewsWire

AptarGroup price target lowered to $145 from $147 at BofA

BofA analyst George Staphos lowered the firm’s price target on AptarGroup (ATR) to $145 from $147 and keeps a Neutral rating on the shares as part of the firm’s preview…

3 months ago - TheFly

AptarGroup Proxy statement: Proxy filing

AptarGroup filed a proxy statement on March 27, 2026, providing details for shareholder voting and corporate governance matters.

4 months ago - Filings

AptarGroup Proxy statement: Proxy filing

AptarGroup filed a proxy statement on March 27, 2026, providing details for shareholder voting and corporate governance matters.

4 months ago - Filings